Japan Medical Devices Market Size, Share & Industry Analysis, By Type (Orthopedic Devices, Cardiovascular Devices, Diagnostic Imaging, In-vitro Diagnostics, Minimally Invasive Surgery (MIS), Wound Management, Diabetes Care Devices, Ophthalmic Devices, Dental Devices, Nephrology Devices, General Surgery, and Others), By End-User (Hospitals & ASCs, Clinics, and Others) and Country Forecast, 2025-2032

The Japan medical devices market size was valued at USD 39.06 billion in 2024. The market is projected to grow from USD 41.36 billion in 2025 to USD 64.40 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period.

Medical devices are the tools used by healthcare facilities for diagnosis and treatment. Medical devices include injection pens, capnography meters, ultrasound systems, pacemakers, etc. The increasing prevalence of chronic conditions such as cancer, diabetes, etc., along with advancements in healthcare infrastructure, has been driving the demand for innovative diagnostic and therapeutic solutions.

• For instance, as per the data published by the World Health Organization (WHO) in 2022, around 1,005,157 new cancer cases were registered in Japan, and around 2,741,718 prevalent cases were observed in the country. Moreover, out of the total cancer cases, colorectal cancer was the most prevalent type of cancer, accounting for 14.5% of the total new cancer cases.

Major market players such as Johnson & Johnson, Medtronic, and Stryker are among the key players focusing on the expansion of their product portfolio with an aim to fuel their revenue growth.

Market Dynamics

Market Drivers

High Burden of Chronic Diseases is Responsible for Market Growth

The prevalence of chronic diseases such as cancer, infectious diseases, cardiac disorders, etc. has been growing significantly in Japan. This factor has been fueling demand for effective diagnosis and treatment options.

• For instance, as per the data published by the International Diabetes Federation, in 2024, around 8,970,500 of the adult population suffered from diabetes, accounting for 8.1% of the total adult population.
• Similarly, as per the data published by the Alzheimer's Association in 2025, around 7.2 million people have Alzheimer’s Disease. The disease is more prevalent among the elderly population aged 85 and above, accounting for 33.4% of the total cases.

Moreover, accidental injuries are also increasing in the country. This factor has been fueling the number of hospital admissions.

• For instance, as per the data published by the Nippon Communications Foundation, in January 2024, traffic accidents reached 307,911, with a year-on-year growth of 7,072. Also, the number of people injured in accidents reached 365,027, experiencing an increase of 8,426.

The growing burden of chronic diseases and accidental injuries has fueled the demand for diagnostics and treatment devices in healthcare facilities, fueling the Japan medical devices market growth.

Growing Geriatric Population has Been Fueling Market Growth

The country’s elderly demographic has been driving the demand for home-care and long-term monitoring medical devices, thereby fueling the market growth.

Favorable Government Initiatives and Reimbursement Facilities Increase Novel Product Launches

Supportive Japanese government policies and reimbursement reforms facilitate new innovations and advanced product launches, thereby enhancing the market in the country.

Market Restraints

High Cost of Medical Equipment, along with Lack of Skilled Laborers, Limits Market Growth 

The growing burden of chronic conditions has been fueling the demand for advanced medical devices. However, the high cost of these devices limits their adoption in the country.  

• For instance, the cost of capnometers ranges between USD 1,000.0 to USD 22,000.0, and sometimes can go higher than that.
• Similarly, the optical coherence tomography (OCT) device can cost between USD 8,000.0 to USD 70,000.0.

Moreover, Japan is also experiencing low availability of skilled healthcare professionals. This is due to the growing aging population and low birth rates. The demand for skilled professionals is increasing in various sectors, including healthcare and manufacturing.

Such high costs of these devices and the lack of a skilled workforce have been limiting the penetration of medical devices in the country.

Market Opportunities

Increasing Number of Devices Clinical Trials in Japan is Expected to Fuel Market Growth in Coming Years

Medical device manufacturers have increased their focus on conducting clinical trials for their medical equipment in Japan. This factor is expected to create awareness regarding these products in the country.

• For instance, Amgen initiated a phase 3 clinical trial in April 2024 to study the safety and efficacy of Rocatinlimab among patients with moderate-to-severe atopic dermatitis. The drug comes in autoinjector devices so that it can be self-administered conveniently. The expected completion date of the study is in 2026. The study was conducted at 47 locations; 7 locations were in Japan.

The increasing preference of market players in conducting clinical trials in the country is expected to create awareness regarding these products. It would create significant opportunities for market growth during the forecast period.

Market Challenges

Stringent Regulatory Scenario Limits Market Growth

Stringent regulatory scenarios increase the clinical trial processes, resulting in delayed product launch and increasing the overall cost of the development process, thereby acting as a challenge for market growth.

Growing Competition Among the Market Players Acts as a Challenge for their Growth

Emergence of new players in the market with similar offerings creates competition and acts as a challenge to the revenue growth of the companies.

Download Free sample to learn more about this report.

Japan Medical Devices Market Trends

Market Players have been Emphasizing on Development and Launch of Novel Products

In order to fulfill the growing demand for technologically advanced products, market players have been focusing on developing and launching novel products.

• In April 2025, Medtronic announced that its robotic-assisted urologic surgery-based Expand URO Investigational Device Exemption (IDE) clinical study met primary safety and effectiveness endpoints.
• In March 2025, Medtronic announced the launch of the Aurora EV-ICDTM MRI device and the Epsila EVTM MRI Lead, indicated for treating ventricular arrhythmias, in Japan.

Segmentation Analysis

By Type

Emphasis of Market Players on New Product Launches is Responsible for In-vitro Diagnostics Segment’s Growth

The market is segmented by type into cardiovascular devices, orthopedic devices, diagnostic imaging, minimally invasive surgery (MIS), in-vitro diagnostics, wound management, diabetes care devices, ophthalmic devices, dental devices, nephrology devices, general surgery, and others.

The in-vitro diagnostics segment accounted for a significant portion of the market share in 2024 by accounting for a major portion of the Japan medical devices market share. The segment’s dominance is attributed to the increasing focus of the market players on new product launches.

• For instance, in March 2025, Sysmex Corporation announced the commercialization of the HISCL C-Peptide Assay Kit, a C-peptide immunoassay parameter indicated for diabetes diagnosis.

Moreover, the dental segment is expected to grow at the fastest CAGR during the forecast period. The segment’s growth is attributed to the growing burden of dental disorders and the increasing focus of the market players on new product launches.

• For instance, in October 2022, SheepMedical Co., Ltd., a medical technology company, announced the launch of KiyoClear clear aligners in the Asian market, including Japan.

To know how our report can help streamline your business, Speak to Analyst

By End-User

Increasing Number of Hospital Beds per Patient Population is Responsible for Segment’s Dominance

By end user, the market is segmented into hospitals & ASCs, clinics, and others.

The hospitals & ASCs segment dominated the market in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment’s growth is attributed to the improvement in the hospital infrastructure and the availability of beds in the hospitals for the patients.

• For instance, according to the data published by the Ministry of Health, Labour and Welfare of Japan, there were 710 general beds in hospitals per 100,000 population in 2023, experiencing a growth of 0.9% from 2014.

The clinics segment is expected to grow at the fastest CAGR during the forecast period. The segment’s growth is attributed to the country's growing burden of chronic conditions.

Competitive Landscape

Key Market Players

Increasing Focus of Market Players on Novel Product Launches to Enhance their Offerings

Market players such as Johnson & Johnson, GE Healthcare, Medtronic, and Stryker accounted for a significant portion of the Japan medical devices market share in 2024. These players have been focusing on partnerships and acquisitions to expand their product offerings.

• For instance, in July 2024, Stryker acquired Artelon, Inc., a soft tissue fixation products manufacturing company. With this acquisition, the company aimed to enhance its product offerings globally and to improve the quality of life.

Other players such as Abbott, Koninklijke Philips N.V., Siemens Healthineers AG, BD, and Cardinal Health have been focusing on new product launches, partnerships, and collaborations to expand their product offerings in the country.

• For instance, in June 2020, Koninklijke Philips N.V. announced the launch of Lumify, a handheld ultrasound diagnostic in Japan.

LIST OF KEY JAPAN MEDICAL DEVICES COMPANIES PROFILED

• Medtronic (Ireland)
• Johnson & Johnson (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Hoffmann-La Roche Ltd. (Switzerland)
• Boston Scientific Corporation (U.S.)
• Fresenius Medical Care AG (Germany)
• GE Healthcare (U.S.)
• Siemens Healthineers AG (Germany)
• Stryker (U.S.)
• Abbott (U.S.)
• BD (U.S.)
• Cardinal Health (U.S.)
• Sysmex Corporation (Japan)

KEY INDUSTRY DEVELOPMENTS

• April 2025 – Medtronic announced the U.S. Food and Drug Administration (FDA) approval for the OmniaSecure, a defibrillation lead for placement in the right ventricle.
• July 2025 – Koninklijke Philips N.V. collaborated with Epic, an electronic health record (EHR) company, with an aim to incorporate its cardiac ambulatory monitoring and diagnostics services with Aura, a specialty diagnostics suite.
• July 2025 – GE Healthcare announced the commercialization of Definium, a floor-mounted digital X-ray device.
• June 2025 – Sysmex Corporation and Nippon Life Insurance Company collaborated in the field of healthcare, intending to conduct R&D of a disease risk assessment model for chronic diseases such as cancer, cardiovascular diseases, etc.
• October 2024 – Johnson & Johnson launched the Japan Smart Healthy Aging QuickFire Challenge 2024. This challenge invited Japan-based and global innovators to submit promising medical technologies with an aim to improve current healthcare offerings.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation